Shilpa Medicare (Mid Cap - Potential Multibagger) Share Target 2026, 2027 To 2035
|
Shilpa Medicare Limited |
|||
|
Price: ₹532.75 (-2.56%) | ||
| 52 Week Low: ₹259.50 52 Week High: ₹581.00 |
|||
| Market Capital: 8,095.13 Crore (Mid-cap) | |||
| Healthcare -> Drug Manufacturers - Specialty & Generic | |||
Share Price HistorySHILPAMED FinancialsTomorrow TargetYearly TargetsDividend HistoryBonus HistorySplit History
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Shilpa Medicare Share Price Target For 2026
- 1.1.1: Shilpa Medicare Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Shilpa Medicare Share Price Target For 2027
- 1.2.1: Shilpa Medicare Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Shilpa Medicare Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Shilpa Medicare Brief Company Overview
- 4: Shilpa Medicare Financial Performance
- 4.0.1: Is Shilpa Medicare A Good Buy For Long Term?
Shilpa Medicare, a Mid Cap company in the Drug Manufacturers - Specialty & Generic Industry has delivered 364.1% returns in 3-year showing 9.1% quarterly revenue growth, making it a potential Multibagger.
To predict the Shilpa Medicare's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Shilpa Medicare Share Price Target For 2026
The line chart displays the monthly closing prices of Shilpa Medicare with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Shilpa Medicare shares in 2026, see the table below.
Shilpa Medicare Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 581.88 (+9.22%) | Volatility: ATR T1 |
| 2026 Target 2 | 569.05 (+6.81%) | Volatility: BB Upper |
| 2026 Target 1 | 535.88 (+0.58%) | Trend: EMA9 |
| Current Price | 532.75 | Shilpa Medicare's share price as of 15 Jun 2026 |
| Stop Loss 1 | 483.62 (-9.23%) | Volatility: ATR S1 |
| Stop Loss 2 | 459.73 (-13.71%) | Volatility: BB Lower |
| Stop Loss 3 | 459.51 (-13.75%) | Trend: SMA50 |
Short-Term Technical Outlook
Current Technical Position: Shilpa Medicare is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹459.51 serves as the nearest technical reference point.
Historical Returns: 3-month: +68.59% | 6-month: +64.56% | 1-year: +10.93%
Shilpa Medicare Share Price Target For 2027
The line chart displays the monthly closing prices of Shilpa Medicare with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Shilpa Medicare shares in 2027, see the table below.
Shilpa Medicare Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 581.88 (+9.22%) | Volatility: ATR T1 |
| 2027 Target 2 | 569.05 (+6.81%) | Volatility: BB Upper |
| 2027 Target 1 | 535.88 (+0.58%) | Trend: EMA9 |
| Current Price | 532.75 | Shilpa Medicare's share price as of 15 Jun 2026 |
| Stop Loss 1 | 483.62 (-9.23%) | Volatility: ATR S1 |
| Stop Loss 2 | 459.73 (-13.71%) | Volatility: BB Lower |
| Stop Loss 3 | 459.51 (-13.75%) | Trend: SMA50 |
Long-Term Technical Outlook
52-Week Range Analysis: Shilpa Medicare is currently trading near its 52-week high of ₹581, showing strong yearly momentum.
Long-Term Trend Analysis: The stock shows mixed long-term signals, trading near key moving averages.
Long-Term Performance: 1-year: +10.93% | 3-year: +364.13% | 5-year: +104.7%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Shilpa Medicare Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹532.75 | ||
| 2026 | ₹606.50 | +13.843266072267% | ₹615.60 |
| 2027 | ₹821.94 | +35.521846661171% | ₹834.27 |
| 2028 | ₹1,266.07 | +54.034357739008% | ₹1,285.06 |
| 2029 | ₹1,749.31 | +38.168505690839% | ₹1,775.55 |
| 2030 | ₹2,428.18 | +38.807872818426% | ₹2,464.60 |
| 2031 | ₹3,258.50 | +34.195158513784% | ₹3,307.38 |
| 2032 | ₹4,150.56 | +27.376400184134% | ₹4,212.82 |
| 2033 | ₹5,545.76 | +33.614741143364% | ₹5,628.95 |
| 2034 | ₹6,819.37 | +22.965472721503% | ₹6,921.66 |
| 2035 | ₹8,440.91 | +23.778442876688% | ₹8,567.52 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Shilpa Medicare Brief Company Overview
Shilpa Medicare Limited: A Global Healthcare Leader Founded in 1987, Shilpa Medicare Limited has established itself as a prominent player in the pharmaceutical industry. The company's diverse product portfolio includes oncology and non-oncology APIs, new drug delivery...
systems, peptides/biotech products, and specialty chemicals. With operations spanning India, the United States, Europe, and other international markets, Shilpa Medicare has a global footprint. The company's commitment to quality and innovation is reflected in its contract manufacturing services for a variety of dosage forms. Shilpa Medicare's reputation in the industry is built on its high standards of manufacturing and adherence to regulatory compliance. The company's commitment to research and development ensures that it remains at the forefront of innovation in the healthcare sector.Shilpa Medicare Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 4,933.06 Crore | Market valuation of Shilpa Medicare's shares. |
| Revenue (TTM) | 1,124.75 Crore | Total revenue generated by Shilpa Medicare over the past twelve months. |
| Net Income (TTM) | -67.06 Lakh | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 13.69% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -0.06% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+9.1% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+13.65% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
48.76 | Company's total debt divided by total shareholder equity. |
| Total Debt | 865.43 Crore | Sum of Shilpa Medicare's current & long-term financial obligations. |
| Total Cash | 23.97 Crore | Total amount of liquid funds available to Shilpa Medicare. |
| Beta | 0.77 | Beta is less than 1 indicating that the Shilpa Medicare's price is less volatile than the market. |
Is Shilpa Medicare A Good Buy For Long Term?
Shilpa Medicare's recent financial data indicates mixed signals. While its past performance and revenue growth have been impressive, its negative net profit and high debt raise concerns. The low profit margin suggests operational inefficiencies. For long-term investment, investors may want to consider more financially stable companies with consistent profitability and lower debt levels.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
